In currently on-going clinical evaluations, the new generation of AD diagnostic PET tracers are specifically designed to target tau aggregates to clearly mark the tauopathy-induced neurotoxicity in AD, whilst the efficacy of the recently FDA-approved AD drug leqembi, targeting AD Aβ, was confirmed by clinical trials in MCI and prodromal AD patients. The gene discussed is MAPT; the disease is Alzheimer disease.